YUHSpace: Dept. of Internal Medicine (내과학교실)

YUHSpace

BROWSE

YUHSpace1. College of Medicine (의과대학)Dept. of Internal Medicine (내과학교실)

Dept. of Internal Medicine (내과학교실)

Researcher List

Keyword Cloud

Journal Categories

Hot Articles

Trastuzumab in combination with chemotherapy versus chemotherapy alone f...

Yung-Jue Bang ; Eric Van Cutsem ; Andrea Feyereislova ; Hyun C Chung ; Lin Sh... LANCET, Vol.376(9742) : 687-697, 2010

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Jean-Charles Soria ; Yuichiro Ohe ; Johan Vansteenkiste ; Thanyanan Reungwetw... NEW ENGLAND JOURNAL OF MEDICINE, Vol.378(2) : 113-125, 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorecta...

Eric Van Cutsem ; Claus-Henning Köhne ; Erika Hitre ; Jerzy Zaluski ; Chung-R... NEW ENGLAND JOURNAL OF MEDICINE, Vol.360(14) : 1408-1417, 2009

PDF Read more

This table browses all dspace content
Issue Date	Title	Journal Title
2022	Soluble RAGE attenuates Ang II-induced arterial calcification via inhibiting AT1R-HMGB1-RAGE axis	ATHEROSCLEROSIS
2022	Prognostic Impact of Chronic Vasodilator Therapy in Patients With Vasospastic Angina	JOURNAL OF THE AMERICAN HEART ASSOCIATION
2022	Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant	CLINICAL CANCER RESEARCH
2022	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment	THERAPEUTIC ADVANCES IN HEMATOLOGY
2022	Association between Physical Activity and the Risk of Mortality and Hospitalization in Older Korean Adults with Heart Failure	REVIEWS IN CARDIOVASCULAR MEDICINE
2022	Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)	LUNG CANCER
2022	Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials	JOURNAL FOR IMMUNOTHERAPY OF CANCER
2022	Clinical Implications of Atrial Fibrillation Detection Using Wearable Devices in Patients With Cryptogenic Stroke (CANDLE-AF) Trial: Design and Rationale	FRONTIERS IN CARDIOVASCULAR MEDICINE
2022	Cardiovascular risk assessment tools in Asia	JOURNAL OF CLINICAL HYPERTENSION
2022	유전성 혈관부종의 진단과 치료: 전문가 의견서	ALLERGY ASTHMA & RESPIRATORY DISEASE
2022	A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors	JOURNAL OF THORACIC ONCOLOGY
2022	Comparisons Between Normocalcemic Primary Hyperparathyroidism and Typical Primary Hyperparathyroidism	JOURNAL OF KOREAN MEDICAL SCIENCE
2022	Association of Physical Activity With Primary Cardiac Arrest Risk in the General Population: A Nationwide Cohort Study of the Dose-Response Relationship	MAYO CLINIC PROCEEDINGS
2022	New-onset class III lupus nephritis with multi-organ involvement after COVID-19 vaccination	KIDNEY INTERNATIONAL
2022	Aspirin and Statin Therapy for Nonobstructive Coronary Artery Disease: Five-year Outcomes from the CONFIRM Registry	RADIOLOGY-CARDIOTHORACIC IMAGING
2022	Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results	ANNALS OF ONCOLOGY
2022	Efficacy of Endoscopic and Surgical Treatments for Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-Analysis	JOURNAL OF PERSONALIZED MEDICINE
2022	Updated efficacy and safety of entrectinib in patients (pts) with NTRK fusion-positive (NTRK-fp) NSCLC	ANNALS OF ONCOLOGY
2022	Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON	ANNALS OF ONCOLOGY
2022	Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)	ANNALS OF ONCOLOGY